2015 Q4 Form 10-K Financial Statement
#000156459016014403 Filed on March 10, 2016
Income Statement
| Concept | 2015 Q4 | 2015 | 2014 Q4 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | -100.0% | |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $2.870M | $11.22M | $2.610M |
| YoY Change | 9.96% | 30.62% | 65.19% |
| % of Gross Profit | |||
| Research & Development | $7.157M | $25.95M | $4.701M |
| YoY Change | 52.24% | 120.44% | 226.46% |
| % of Gross Profit | |||
| Depreciation & Amortization | $60.00K | $192.0K | $40.00K |
| YoY Change | 50.0% | 52.38% | 0.0% |
| % of Gross Profit | |||
| Operating Expenses | $10.03M | $37.17M | $7.308M |
| YoY Change | 37.23% | 82.57% | 142.39% |
| Operating Profit | |||
| YoY Change | |||
| Interest Expense | $689.0K | $2.432M | $163.0K |
| YoY Change | 322.7% | -327.29% | -62.09% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$687.0K | -$2.422M | -$159.0K |
| YoY Change | 332.08% | -20.93% | -66.24% |
| Pretax Income | -$10.71M | -$39.59M | -$7.470M |
| YoY Change | 43.37% | 69.62% | 114.66% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$10.72M | -$39.59M | -$7.467M |
| YoY Change | 43.51% | 69.63% | 114.57% |
| Net Earnings / Revenue | |||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$3.909M | -$15.59M | -$3.662M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 20.13M shares | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2015 Q4 | 2015 | 2014 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $75.91M | $75.91M | $51.17M |
| YoY Change | 48.35% | 48.35% | 832.06% |
| Cash & Equivalents | $219.4K | $75.91M | $51.17M |
| Short-Term Investments | |||
| Other Short-Term Assets | |||
| YoY Change | |||
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $1.390M | $1.390M | $1.660M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $77.30M | $77.30M | $52.84M |
| YoY Change | 46.31% | 46.29% | 719.54% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $576.0K | $580.0K | $342.0K |
| YoY Change | 68.42% | 70.59% | 39.59% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $347.0K | $350.0K | $215.0K |
| YoY Change | 61.4% | 59.09% | 59.26% |
| Total Long-Term Assets | $923.0K | $930.0K | $557.0K |
| YoY Change | 65.71% | 69.09% | 46.58% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $77.30M | $77.30M | $52.84M |
| Total Long-Term Assets | $923.0K | $930.0K | $557.0K |
| Total Assets | $78.23M | $78.23M | $53.39M |
| YoY Change | 46.51% | 46.53% | 682.09% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $2.226M | $2.230M | $1.255M |
| YoY Change | 77.37% | 76.98% | 37.31% |
| Accrued Expenses | $6.459M | $6.460M | $3.648M |
| YoY Change | 77.06% | 76.99% | 60.42% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| Long-Term Debt Due | $7.650M | $7.650M | $3.120M |
| YoY Change | 145.19% | 145.19% | -0.32% |
| Total Short-Term Liabilities | $16.34M | $16.34M | $8.061M |
| YoY Change | 102.67% | 102.73% | -46.78% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $12.67M | $12.67M | $0.00 |
| YoY Change | -100.0% | ||
| Other Long-Term Liabilities | $473.0K | $470.0K | $7.000K |
| YoY Change | 6657.14% | 4600.0% | -41.67% |
| Total Long-Term Liabilities | $13.15M | $13.14M | $7.000K |
| YoY Change | 187685.71% | 131300.0% | -99.84% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $16.34M | $16.34M | $8.061M |
| Total Long-Term Liabilities | $13.15M | $13.14M | $7.000K |
| Total Liabilities | $29.48M | $29.48M | $8.068M |
| YoY Change | 265.42% | 265.3% | -58.84% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$161.4M | -$121.8M | |
| YoY Change | 32.51% | 23.71% | |
| Common Stock | $210.1M | $167.1M | |
| YoY Change | 25.74% | ||
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$46.95K | $48.74M | $45.33M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $78.23M | $78.23M | $53.39M |
| YoY Change | 46.51% | 46.53% | 682.09% |
Cashflow Statement
| Concept | 2015 Q4 | 2015 | 2014 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$10.72M | -$39.59M | -$7.467M |
| YoY Change | 43.51% | 69.63% | 114.57% |
| Depreciation, Depletion And Amortization | $60.00K | $192.0K | $40.00K |
| YoY Change | 50.0% | 52.38% | 0.0% |
| Cash From Operating Activities | -$8.210M | -$31.92M | -$5.610M |
| YoY Change | 46.35% | 67.47% | 71.56% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$140.0K | $277.0K | -$110.0K |
| YoY Change | 27.27% | 23.11% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $20.00K | -$210.0K | $0.00 |
| YoY Change | -625.0% | ||
| Cash From Investing Activities | -$110.0K | -$480.0K | -$110.0K |
| YoY Change | 0.0% | 152.63% | |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $2.628M | ||
| YoY Change | 1777.14% | ||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 6.600M | 57.13M | -900.0K |
| YoY Change | -833.33% | -12.01% | -21.74% |
| NET CHANGE | |||
| Cash From Operating Activities | -8.210M | -31.92M | -5.610M |
| Cash From Investing Activities | -110.0K | -480.0K | -110.0K |
| Cash From Financing Activities | 6.600M | 57.13M | -900.0K |
| Net Change In Cash | -1.720M | 24.73M | -6.620M |
| YoY Change | -74.02% | -45.86% | 49.77% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$8.210M | -$31.92M | -$5.610M |
| Capital Expenditures | -$140.0K | $277.0K | -$110.0K |
| Free Cash Flow | -$8.070M | -$32.20M | -$5.500M |
| YoY Change | 46.73% | 66.95% | 68.2% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2013 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-202000 | |
| CY2015Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2015Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
473000 | |
| CY2015Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
13145000 | |
| CY2015Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
2226000 | |
| CY2015Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
6459000 | |
| CY2014Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
34000 | |
| CY2015Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
16337000 | |
| CY2015Q4 | us-gaap |
Long Term Loans Payable
LongTermLoansPayable
|
12672000 | |
| CY2014Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
7000 | |
| CY2014Q4 | us-gaap |
Liabilities Noncurrent
LiabilitiesNoncurrent
|
7000 | |
| CY2015Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2014Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2014 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
7600000 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.340 | |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.340 | |
| CY2014 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11772000 | |
| CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
9700000 | |
| CY2014 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-3063000 | |
| CY2014 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-23342000 | |
| CY2015 | us-gaap |
Interest Expense
InterestExpense
|
2432000 | |
| CY2015 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2422000 | |
| CY2015 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-39594000 | |
| CY2013 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17143000 | |
| CY2013 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-25.05 | |
| CY2014 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.60 | |
| CY2014 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
885000 | |
| CY2013 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
684330 | |
| CY2013 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
622000 | |
| CY2014 | us-gaap |
Straight Line Rent Adjustments
StraightLineRentAdjustments
|
29000 | |
| CY2013 | us-gaap |
Straight Line Rent Adjustments
StraightLineRentAdjustments
|
-1000 | |
| CY2014 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
126000 | |
| CY2013 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
197000 | |
| CY2014 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
28000 | |
| CY2013 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-7000 | |
| CY2014 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
215000 | |
| CY2013 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
215000 | |
| CY2014Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2015Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | |
| CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
20125049 | |
| CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | |
| CY2015Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
210115000 | |
| CY2014Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
167104000 | |
| CY2015Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-161375000 | |
| CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-121781000 | |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
48743000 | |
| CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
45325000 | |
| CY2015Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
78225000 | |
| CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
53393000 | |
| CY2015Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2014Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2015Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2015Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2015Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2014Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | |
| CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
120000000 | |
| CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
120000000 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
27346780 | |
| CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
27346780 | |
| CY2014Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
20125049 | |
| CY2014 | us-gaap |
Revenues
Revenues
|
80000 | |
| CY2013 | us-gaap |
Revenues
Revenues
|
6000 | |
| CY2013 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
6166000 | |
| CY2014 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-2493000 | |
| CY2014 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-504000 | |
| CY2015 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.56 | |
| CY2015 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
25431332 | |
| CY2014 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
14548516 | |
| CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-80039000 | |
| CY2013 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
35000 | |
| CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
622000 | |
| CY2013 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
2226000 | |
| CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-94299000 | |
| CY2014 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
140000 | |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
885000 | |
| CY2014 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
81526000 | |
| CY2014 | ceru |
Conversion Of Convertible Notes
ConversionOfConvertibleNotes
|
20129000 | |
| CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
187000 | |
| CY2015 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2375000 | |
| CY2015 | us-gaap |
Straight Line Rent Adjustments
StraightLineRentAdjustments
|
-41000 | |
| CY2015 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
192000 | |
| CY2015 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
6000 | |
| CY2015 | us-gaap |
Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
|
739000 | |
| CY2015 | ceru |
Increase Decrease In Accounts Receivable Prepaid Expenses And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpensesAndOtherCurrentAssets
|
-342000 | |
| CY2014 | ceru |
Increase Decrease In Accounts Receivable Prepaid Expenses And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpensesAndOtherCurrentAssets
|
695000 | |
| CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
5402000 | |
| CY2013 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-11219000 | |
| CY2014 | us-gaap |
Interest Paid Net
InterestPaidNet
|
400000 | |
| CY2013 | us-gaap |
Interest Paid Net
InterestPaidNet
|
664000 | |
| CY2014 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
8500000 | |
| CY2013 | us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
8824000 | |
| CY2015 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
3321000 | |
| CY2014 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
3348000 | |
| CY2013 | us-gaap |
Repayments Of Notes Payable
RepaymentsOfNotesPayable
|
3084000 | |
| CY2015 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
359000 | |
| CY2014 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
222000 | |
| CY2013 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
373000 | |
| CY2013 | ceru |
Increase Decrease In Accounts Receivable Prepaid Expenses And Other Current Assets
IncreaseDecreaseInAccountsReceivablePrepaidExpensesAndOtherCurrentAssets
|
209000 | |
| CY2015 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
795000 | |
| CY2014 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
341000 | |
| CY2013 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
14000 | |
| CY2015 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
3283000 | |
| CY2014 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1419000 | |
| CY2013 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-114000 | |
| CY2015 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-31915000 | |
| CY2014 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-19061000 | |
| CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-16614000 | |
| CY2015 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
277000 | |
| CY2014 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
225000 | |
| CY2013 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
7000 | |
| CY2015 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
23000 | |
| CY2014 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
40000 | |
| CY2015 | us-gaap |
Increase In Restricted Cash
IncreaseInRestrictedCash
|
230000 | |
| CY2015 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-484000 | |
| CY2014 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-185000 | |
| CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-7000 | |
| CY2015 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
2628000 | |
| CY2014 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
140000 | |
| CY2013 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
35000 | |
| CY2015 | ceru |
Proceeds From Issuance Public Offering Net
ProceedsFromIssuancePublicOfferingNet
|
37185000 | |
| CY2014 | ceru |
Proceeds From Issuance Public Offering Net
ProceedsFromIssuancePublicOfferingNet
|
59862000 | |
| CY2015 | us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
21000000 | |
| CY2015 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
57133000 | |
| CY2014 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
64932000 | |
| CY2015 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
24734000 | |
| CY2014 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
45686000 | |
| CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
5488000 | |
| CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
16707000 | |
| CY2015 | ceru |
Property And Equipment In Accounts Payable
PropertyAndEquipmentInAccountsPayable
|
177000 | |
| CY2014 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
81526000 | |
| CY2013 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
2226000 | |
| CY2014 | us-gaap |
Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
|
20129000 | |
| CY2014 | ceru |
Reclassification Of Warrants To Additional Paid In Capital
ReclassificationOfWarrantsToAdditionalPaidInCapital
|
424000 | |
| CY2015 | ceru |
Noncash Warrants Issued With Term Loan Facility
NoncashWarrantsIssuedWithTermLoanFacility
|
824000 | |
| CY2015 | us-gaap |
Interest Paid Net
InterestPaidNet
|
1000000 | |
| CY2015 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:12pt;font-family:Times New Roman;font-size:10pt;font-weight:bold;">1.</p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">NATURE OF BUSINESS AND OPERATIONS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Nature of Business<font style="font-weight:normal;"> — Cerulean Pharma Inc. (the “Company”) was incorporated on November 28, 2005, as a Delaware corporation and is located in Waltham, Massachusetts. The Company was formed to develop novel, nanotechnology-based therapeutics in the areas of oncology and other diseases. In 2013, the Company formed a wholly-owned subsidiary, Cerulean Pharma Australia Pty Ltd as an Australian-based proprietary limited company to perform clinical activities in Australia. </font></p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company's operations to date have consisted primarily of raising capital, product research and development, and initial market development. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not generated any revenue related to its primary business purpose to date and is subject to a number of risks similar to those of other development stage life science companies, including dependence on key individuals, competition from other companies, the need for development of commercially viable products, and the need to obtain adequate additional financing to fund the development of its product candidates. The Company is also subject to a number of risks similar to other companies in the industry, including rapid technological change, regulatory approval of products, uncertainty of market acceptance of products, competition from substitute products and larger companies, the need to obtain additional financing, compliance with government regulations, protection of proprietary technology, dependence on third parties, product liability and dependence on key individuals.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has an accumulated deficit of $161.4 million at December 31, 2015. The Company has financed its operations primarily through private placements of its preferred stock, proceeds from borrowings, an initial public offering completed in 2014 and a follow-on offering completed in 2015. The Company has not completed development of any product candidate and has devoted substantially all of its financial resources and efforts to research and development, including preclinical and clinical development. Accordingly, the Company will continue to depend on its ability to raise capital through equity and debt issuances and/or through strategic partnerships. The Company expects to continue to incur significant expenses and increasing operating losses for at least several years. The Company believes that its cash and cash equivalents as of December 31, 2015, will be able to fund operating expenses, debt service and capital expenditure requirements for at least twelve months from our 2015 financial statement issuance date. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Follow-on Offering<font style="font-weight:normal;"> — On April 10, 2015, the Company completed the issuance and sale of 6,716,000 shares of common stock in an underwritten public offering at a price to the public of $6.00 per share. The sale of shares of common stock included 876,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares of common stock. The net proceeds to the Company from this offering were $37.2 million after deducting underwriting discounts and commissions and offering expenses payable by the Company.</font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Initial Public Offering<font style="font-weight:normal;"> — On April 15, 2014, the Company completed the sale of 8,500,000 shares of its common stock in its initial public offering (the “IPO”), at a price to the public of $7.00 per share. On May 7, 2014, the Company completed the sale of an additional 1,069,715 shares of common stock at a price to the public of $7.00 per share under a partial exercise by the underwriters of their option to purchase additional shares of common stock. The sale of shares to the public resulted in net proceeds of $59.9 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. </font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the closing of the IPO, all of the Company’s outstanding redeemable convertible preferred stock and convertible notes automatically converted into shares of common stock as of April 15, 2014, resulting in the issuance by the Company of an additional 9,728,237 shares of common stock. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the completion of the IPO on April 15, 2014, the Company’s outstanding warrants to purchase 1,857,226 shares of the Company’s preferred stock automatically converted into warrants to purchase an aggregate of 128,663 shares of the Company’s common stock and, as a result, the Company reclassified the warrant liability to additional paid-in capital.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"> </p></div> | |
| CY2014Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1490000 | |
| CY2015 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Use of Estimates<font style="font-weight:normal;"> — </font><font style="color:#000000;font-weight:normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</font></p> <p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On an ongoing basis, the Company's management evaluates its estimates, including estimates related to clinical trial accruals, stock-based compensation expense, and reported amounts of revenues and expenses during the reported period. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</p></div> | |
| CY2015 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Concentrations of Credit Risk<font style="font-weight:normal;"> — Financial instruments that subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents are </font><font style="font-weight:normal;">held at one financial institution that management believes to be of high-credit quality. Deposits with this financial institution may exceed the amount of insurance provided on such deposits; however these deposits may be redeemed upon demand and, therefore, bear minimal risk. </font></p></div> | |
| CY2015 | us-gaap |
Derivatives Reporting Of Derivative Activity
DerivativesReportingOfDerivativeActivity
|
<div> <p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Preferred Stock Warrant Liability<font style="font-weight:normal;"> — Freestanding warrants related to shares that are redeemable or contingently redeemable are classified as a liability on the Company’s balance sheets. The Company uses the Black-Scholes option-pricing model to estimate the fair value of the warrants. Changes in the fair value of these warrants are recorded in the statements of operations. </font><font style="font-weight:normal;">All of the Company’s warrants to purchase preferred stock were converted to warrants to purchase common stock upon the Company’s IPO in April 2014. Accordingly, the preferred stock warrant liability was reclassified to additional paid-in capital. </font></p></div> | |
| CY2015 | us-gaap |
Guarantees Indemnifications And Warranties Policies
GuaranteesIndemnificationsAndWarrantiesPolicies
|
<div> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Guarantees and Indemnification<font style="font-weight:normal;"> — As permitted under Delaware law, the Company indemnifies its officers</font><font style="font-weight:normal;"> and directors employees for certain events or occurrences while the officer or director is, or was serving at the Company’s request in such a capacity. The term of the indemnification is for the officer’s or director’s lifetime. </font></p></div> | |
| CY2014Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
117000 | |
| CY2015 | ceru |
Lease Expiration Period Month And Year
LeaseExpirationPeriodMonthAndYear
|
2016-02 | |
| CY2015 | dei |
Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
|
2005-11-28 | |
| CY2015 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2015Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
347000 | |
| CY2015Q4 | ceru |
Unamortized Deferred Financing Costs
UnamortizedDeferredFinancingCosts
|
200000 | |
| CY2015 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-39594000 | |
| CY2014 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-23342000 | |
| CY2013 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-17143000 | |
| CY2015Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1722000 | |
| CY2014Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
1832000 | |
| CY2015Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1146000 | |
| CY2015Q4 | ceru |
Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
|
2631000 | |
| CY2014Q4 | ceru |
Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
|
848000 | |
| CY2015Q4 | ceru |
Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
|
945000 | |
| CY2014Q4 | ceru |
Accrued Manufacturing Expenses Current
AccruedManufacturingExpensesCurrent
|
580000 | |
| CY2015Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1864000 | |
| CY2014Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
983000 | |
| CY2015Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
136000 | |
| CY2014Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
574000 | |
| CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
883000 | |
| CY2014Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
663000 | |
| CY2013Q3 | us-gaap |
Debt Instrument Face Amount
DebtInstrumentFaceAmount
|
8824000 | |
| CY2013Q3 | us-gaap |
Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
|
0.07 | |
| CY2015Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
7945000 | |
| CY2015Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
8544000 | |
| CY2015Q4 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
4511000 | |
| CY2015Q4 | ceru |
Debt Instrument Unamortized Discount And Deferred Financing Cost
DebtInstrumentUnamortizedDiscountAndDeferredFinancingCost
|
676000 | |
| CY2015Q4 | us-gaap |
Loans Payable
LoansPayable
|
20324000 | |
| CY2015Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
500000 | |
| CY2015Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
4296440 | |
| CY2014Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
3689767 | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2126176 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2360682 | |
| CY2015 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
370230 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
661702 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3454926 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
2336878 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1001415 | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.97 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
5.66 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
4.40 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
5.86 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
5.39 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
5.32 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
5.56 | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P6Y8M12D | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y10M24D | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P9Y4M24D | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P7Y8M12D | |
| CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
2701000 | |
| CY2015 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2375000 | |
| CY2014 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
885000 | |
| CY2013 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
622000 | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0145 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0171 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0109 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0202 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0200 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0192 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.51 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.54 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
0.59 | |
| CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.63 | |
| CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.60 | |
| CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
0.79 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
75325000 | |
| CY2014Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
50541000 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
35797 | |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
29442 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
2066 | |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
1715 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
|
3977 | |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
|
3503 | |
| CY2015Q4 | ceru |
Deferred Tax Assets Capitalized Research And Development Cost
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost
|
17715 | |
| CY2014Q4 | ceru |
Deferred Tax Assets Capitalized Research And Development Cost
DeferredTaxAssetsCapitalizedResearchAndDevelopmentCost
|
9938 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
903 | |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Other
DeferredTaxAssetsOther
|
422 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
60458 | |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
45020 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
60458 | |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
45020 | |
| CY2015Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | |
| CY2014Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
0 | |
| CY2015 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
15600000 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.050 | |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.045 | |
| CY2015 | ceru |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.005 | |
| CY2014 | ceru |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.037 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.009 | |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
|
0.008 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.007 | |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
|
0.009 | |
| CY2015 | ceru |
Effective Income Tax Rate Reconciliation Expiration Of State Net Operating Loss
EffectiveIncomeTaxRateReconciliationExpirationOfStateNetOperatingLoss
|
0.000 | |
| CY2014 | ceru |
Effective Income Tax Rate Reconciliation Expiration Of State Net Operating Loss
EffectiveIncomeTaxRateReconciliationExpirationOfStateNetOperatingLoss
|
0.017 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0.004 | |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.008 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.391 | |
| CY2014 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.322 | |
| CY2015 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.000 | |
| CY2014 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.000 | |
| CY2015 | ceru |
Operating Loss Carry Forwards Expiration Period
OperatingLossCarryForwardsExpirationPeriod
|
2035 | |
| CY2014 | ceru |
Operating Loss Carry Forwards Expiration Period
OperatingLossCarryForwardsExpirationPeriod
|
2034 | |
| CY2015 | us-gaap |
Lease Expiration Date1
LeaseExpirationDate1
|
2013-02-28 | |
| CY2015 | us-gaap |
Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
|
P3Y | |
| CY2014Q4 | us-gaap |
Deferred Rent Credit
DeferredRentCredit
|
41000 | |
| CY2015 | ceru |
Lease Commencement Date
LeaseCommencementDate
|
2014-07-11 | |
| CY2015 | ceru |
Lease Termination Date
LeaseTerminationDate
|
2015-12-31 | |
| CY2015 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
920000 | |
| CY2014 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
766000 | |
| CY2013 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
598000 | |
| CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
575000 | |
| CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
690000 | |
| CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
738000 | |
| CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
786000 | |
| CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
830000 | |
| CY2015Q4 | ceru |
Operating Leases Future Minimum Payments Due In Six Years
OperatingLeasesFutureMinimumPaymentsDueInSixYears
|
140000 | |
| CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
3759000 | |
| CY2014Q2 | us-gaap |
Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
|
30000 | |
| CY2015Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5021000 | |
| CY2015Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
6678000 | |
| CY2015Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7092000 | |
| CY2015Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
7157000 | |
| CY2015Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2681000 | |
| CY2015Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2717000 | |
| CY2015Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2954000 | |
| CY2015Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2872000 | |
| CY2015Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
7702000 | |
| CY2015Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
9395000 | |
| CY2015Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
10046000 | |
| CY2015Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
10029000 | |
| CY2015Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3000 | |
| CY2015Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1000 | |
| CY2015Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
4000 | |
| CY2015Q4 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2000 | |
| CY2015Q1 | us-gaap |
Interest Expense
InterestExpense
|
721000 | |
| CY2015Q2 | us-gaap |
Interest Expense
InterestExpense
|
513000 | |
| CY2015Q3 | us-gaap |
Interest Expense
InterestExpense
|
509000 | |
| CY2015Q4 | us-gaap |
Interest Expense
InterestExpense
|
689000 | |
| CY2015Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-718000 | |
| CY2015Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-512000 | |
| CY2015Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-505000 | |
| CY2015Q4 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-687000 | |
| CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8420000 | |
| CY2015Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-9907000 | |
| CY2015Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10551000 | |
| CY2015Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10716000 | |
| CY2015Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.41 | |
| CY2015Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.37 | |
| CY2015Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.39 | |
| CY2015Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.39 | |
| CY2015Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
20350557 | |
| CY2014Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-2914000 | |
| CY2014Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7403000 | |
| CY2014Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5558000 | |
| CY2015Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
26690673 | |
| CY2015Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
27307103 | |
| CY2015Q4 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
27346780 | |
| CY2014Q1 | us-gaap |
Revenues
Revenues
|
47000 | |
| CY2014Q2 | us-gaap |
Revenues
Revenues
|
33000 | |
| CY2014Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1495000 | |
| CY2014Q2 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2648000 | |
| CY2014Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2928000 | |
| CY2014Q4 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
4701000 | |
| CY2014Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1510000 | |
| CY2014Q2 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2029000 | |
| CY2014Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2441000 | |
| CY2014Q4 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2607000 | |
| CY2014Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
3005000 | |
| CY2014Q2 | us-gaap |
Operating Expenses
OperatingExpenses
|
4677000 | |
| CY2014Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
5369000 | |
| CY2014Q4 | us-gaap |
Operating Expenses
OperatingExpenses
|
7308000 | |
| CY2014Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
1000 | |
| CY2014Q2 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2000 | |
| CY2014Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
2000 | |
| CY2014Q4 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
4000 | |
| CY2014Q1 | us-gaap |
Interest Expense
InterestExpense
|
461000 | |
| CY2014Q2 | us-gaap |
Interest Expense
InterestExpense
|
268000 | |
| CY2014Q3 | us-gaap |
Interest Expense
InterestExpense
|
191000 | |
| CY2014Q4 | us-gaap |
Interest Expense
InterestExpense
|
163000 | |
| CY2014Q2 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-2493000 | |
| CY2014Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-504000 | |
| CY2014Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
44000 | |
| CY2014Q2 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-2759000 | |
| CY2014Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-189000 | |
| CY2014Q4 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-159000 | |
| CY2014Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-7467000 | |
| CY2014Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-3.70 | |
| CY2014Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.44 | |
| CY2014Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.28 | |
| CY2014Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.37 | |
| CY2014Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
786986 | |
| CY2014Q2 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
16883716 | |
| CY2014Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
20124574 | |
| CY2014Q4 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
20125009 |
